<DOC>
	<DOC>NCT02801383</DOC>
	<brief_summary>to assess the efficacy and safety of recombinant human interferon α-2b gel (Yallaferon®) for the treatment of patients with cervical HPV-16 and/or HPV-18 infections; to analyze the HPV type infections and clinical negative conversion.</brief_summary>
	<brief_title>Recombinant Human Interferon a-2b Gel for HPV-16 and/ or HPV-18 Gynecological Infections</brief_title>
	<detailed_description>100 patients with positive HPV-16 and HPV-18 infection are randomized into interferon gel group and control group at ratio of 1:1 (50 patients in treatment group and 50 patients in control group). The patients in treatment group received 1g recombinant human α-2b interferon gel every other day for consecutive 6-10 courses of treatment, whereas no treatment was conducted in control group.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Age 25 to 65 years of age with the sex life of female patients; HPV DNA typing test for HPV16 and/ or HPV18 positive in 1 month. Patients with cervical intraepithelial neoplasia Ⅱ / Ⅲ, cervical cancer; Associated with fungal vaginitis, trichomonas vaginitis, HIV positive patients; Associated with acute, severe bacterial or viral infection; Autoimmune diseases; Within 3 months before screening patients used corticosteroids, immunosuppressants or other antiviral drugs; Allergies or allergy to the drug known ingredients; History of suffering CNS diseases, epilepsy and/or psychological disorder; Pregnant and lactating women; The researchers do not consider it appropriate clinical trials.</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>